PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT- A UK PERSPECTIVE
Abstract
Authors
DM Jensen P Marcellin A Urspruch K Papadakis D Tonev